Improvement in liver histology among Asian patients with chronic hepatitis B after long-term treatment with entecavir

Liver International

Volumn 33, Issue 4, 2013, Pages 650-651

  Tong, Myron J ^a   Kowdley, Kris V ^b   Pan, Calvin ^c   Hu, Ke Qin ^d   Chang, Ting Tsung ^e   Han, Kwang Hyub ^f   Yoon, Seung Kew ^g   Goodman, Zachary D ^h   Beebe, Suzanne ⁱ   Iloeje, Uchenna ⁱ   Tang, Hong ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^f Yonsei University College of Medicine   (South Korea)

^g The Catholic University of Korea   (South Korea)

^h ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

ⁱ BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; VIRUS DNA;

ADULT; ASIAN; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; LETTER; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; LONG TERM CARE; MALE; TREATMENT DURATION;

ADULT; ANTIVIRAL AGENTS; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BIOPSY; DRUG ADMINISTRATION SCHEDULE; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875042752     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12121     Document Type: Letter

References (7)

1. Tong MJ, Pan CQ, Hann HW, et al. The management of chronic hepatitis B in Asian Americans. Dig Dis Sci 2011; 56: 3143-62.
2. Chang TT, Lai CL, Kew YS, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-30.
3. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93.
4. Pan CQ, Tong M, Kowdley KV, et al. High rates of viral suppression after long-term entecavir treatment of Asian patients with hepatitis B e antigen-positive chronic hepatitis B. Clin Gastroenterol Hepatol 2012; 10: 1047-50.
5. Yokosuka O, Takaguchi K, Fujioka S, et al. Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol 2010; 52: 791-9.
6. Kobashi H, Miyake Y, Ikeda F, et al. Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatol Res 2011; 41: 405-16.
7. Karino Y, Toyota J, Kumada H, et al. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int 2010; 4: 414-22.